IN2014CN02448A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02448A
IN2014CN02448A IN2448CHN2014A IN2014CN02448A IN 2014CN02448 A IN2014CN02448 A IN 2014CN02448A IN 2448CHN2014 A IN2448CHN2014 A IN 2448CHN2014A IN 2014CN02448 A IN2014CN02448 A IN 2014CN02448A
Authority
IN
India
Prior art keywords
glucagon peptides
obesity
treatment
present
peptides
Prior art date
Application number
Other languages
English (en)
Inventor
Jesper F Lau
Thomas Kruse
Henning Thøgersen
Ulrich Sensfuss
Peter Kresten Nielsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IN2014CN02448A publication Critical patent/IN2014CN02448A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
IN2448CHN2014 2011-09-23 2012-09-21 IN2014CN02448A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11182476 2011-09-23
US201161539148P 2011-09-26 2011-09-26
PCT/EP2012/068649 WO2013041678A1 (en) 2011-09-23 2012-09-21 Novel glucagon analogues

Publications (1)

Publication Number Publication Date
IN2014CN02448A true IN2014CN02448A (bg) 2015-06-19

Family

ID=47911932

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2448CHN2014 IN2014CN02448A (bg) 2011-09-23 2012-09-21

Country Status (17)

Country Link
US (4) US8541368B2 (bg)
EP (1) EP2758426B1 (bg)
JP (2) JP6352806B2 (bg)
KR (1) KR20140070612A (bg)
CN (1) CN104093735B (bg)
AR (1) AR088161A1 (bg)
AU (1) AU2012311484B2 (bg)
BR (1) BR112014006684A2 (bg)
CA (1) CA2849673A1 (bg)
IL (1) IL231199A0 (bg)
IN (1) IN2014CN02448A (bg)
MX (1) MX354705B (bg)
MY (1) MY167234A (bg)
RU (2) RU2610175C2 (bg)
TW (1) TWI596110B (bg)
WO (1) WO2013041678A1 (bg)
ZA (1) ZA201401603B (bg)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101005857A (zh) * 2004-07-08 2007-07-25 诺和诺德公司 多肽延长标记
SG177609A1 (en) 2009-07-13 2012-02-28 Zealand Pharma As Acylated glucagon analogues
RU2610175C2 (ru) * 2011-09-23 2017-02-08 Ново Нордиск А/С Новые аналоги глюкагона
KR102184241B1 (ko) 2012-05-03 2020-12-01 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 작용제 화합물 및 방법
MX356957B (es) * 2012-07-23 2018-06-20 Zealand Pharma As Analogos del glucagon.
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
UA116553C2 (uk) 2012-12-21 2018-04-10 Санофі Пептидна сполука - агоніст рецептора glp-1 i glp
DK2986313T3 (da) * 2013-04-18 2019-08-12 Novo Nordisk As Stabile, protraherendede glp-1/glucagonreceptor-co-agonister til medicinsk anvendelse
WO2014170496A1 (en) * 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
WO2014202727A1 (en) 2013-06-20 2014-12-24 Novo Nordisk A/S Glp-1 derivatives and uses thereof
TWI666220B (zh) 2013-10-17 2019-07-21 丹麥商西蘭製藥公司 醯化升糖素類似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
BR112016016321A2 (pt) 2014-02-18 2017-10-03 Novo Nordisk As Derivados de análogos de glucagon estáveis, seus usos, e composição farmacêutica
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
WO2015185640A1 (en) * 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104926934B (zh) 2014-09-23 2016-11-09 蒋先兴 胃泌酸调节素类似物
WO2016055610A1 (en) * 2014-10-10 2016-04-14 Novo Nordisk A/S Stable glp-1 based glp-1/glucagon receptor co-agonists
TWI705973B (zh) 2014-10-29 2020-10-01 丹麥商西蘭製藥公司 Ｇｉｐ促效劑化合物及方法
CN106999602B (zh) 2014-11-27 2022-02-01 诺和诺德股份有限公司 Glp-1衍生物及其用途
EP3233898A1 (en) 2014-12-17 2017-10-25 Novo Nordisk A/S Glp-1 derivatives and uses thereof
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
TWI707867B (zh) 2015-04-16 2020-10-21 丹麥商西蘭製藥公司 醯化之昇糖素類似物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US10308701B2 (en) 2015-07-22 2019-06-04 Purdue Research Foundation Modified glucagon molecules
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2017121850A1 (en) * 2016-01-13 2017-07-20 Novo Nordisk A/S Egf(a) analogues with fatty acid substituents
BR112020000373B1 (pt) * 2017-07-13 2022-05-10 Fuji Oil Holdings Inc Peptídeos, agentes que conferem sabor encorpado a um alimento e métodos para produzir um alimento e para para conferir um sabor encorpado a um alimento
CN110945017B (zh) 2017-07-19 2024-07-16 诺和诺德股份有限公司 双功能化合物
CN111164128A (zh) 2017-09-29 2020-05-15 韩美药品株式会社 包含作为接头的非肽基聚合物偶联的脂肪酸衍生物化合物的蛋白复合物及其制备方法
CN113396156A (zh) 2019-02-05 2021-09-14 伊莱利利公司 胰高血糖素类似物激动剂及其使用方法
EP4076492A4 (en) * 2019-12-20 2024-01-17 Merck Sharp & Dohme LLC PCSK9 ANTAGONIST COMPOUNDS
IL303127A (en) * 2020-12-18 2023-07-01 Novo Nordisk As GLP-1 and amylin receptor co-agonists
IL304214B1 (en) 2021-01-20 2024-09-01 Viking Therapeutics Inc Preparations and methods for the treatment of metabolic and liver disorders
CN113759048B (zh) * 2021-10-14 2022-06-21 成都普康唯新生物科技有限公司 一种十八烷二酸单叔丁酯检验方法

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
ZA90533B (en) 1989-02-01 1990-10-31 Shionogi & Co A method for the production of glucagon
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5480867A (en) * 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
IL124109A (en) 1995-09-08 2001-10-31 Novo Nordisk As Pharmaceutical composition of 2-alkylpyrrolidines for use in the manufacture of medicaments for the treatment of diabetes
EP0876379A1 (en) 1996-01-17 1998-11-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
AU2995497A (en) 1996-07-26 1997-11-19 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
WO1998008871A1 (en) 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-1 derivatives
DK0958296T3 (da) 1996-12-31 2003-08-18 Reddys Lab Ltd Dr Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
JP2001518069A (ja) 1997-05-02 2001-10-09 ドクター・レディーズ・リサーチ・ファウンデーション 低脂質性、抗高血圧性特性を有する新規な抗糖尿病化合物、それらの製造方法及びそれらを含有する薬学的組成物
AU749271B2 (en) 1997-07-01 2002-06-20 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
CA2294830A1 (en) 1997-07-16 1999-01-28 John Bondo Hansen Fused 1,2,4-thiadiazine derivatives, their preparation and use
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
AU6966498A (en) 1997-12-02 1998-10-30 Dr. Reddy's Research Foundation Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypol ipidaemic and antihypertensive properties
AU6325599A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
EP1123267A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123279A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
WO2000023416A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
AU6325899A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
PL348237A1 (en) 1998-12-18 2002-05-20 Novo Nordisk As Fused 1,2,4-thiadiazine derivatives, their preparation and use
WO2000041121A1 (en) 1999-01-07 2000-07-13 Ccrewards.Com Method and arrangement for issuance and management of digital coupons and sales offers
EP1147094A1 (en) 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
AU3033100A (en) 1999-01-18 2000-08-01 Boehringer Ingelheim International Gmbh Substituted imidazoles, their preparation and use
EP1173438A1 (en) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
AU2953699A (en) 1999-04-16 2000-11-02 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
WO2000063189A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
IL145958A0 (en) 1999-04-16 2002-07-25 Reddy Research Foundation Polymorphic form of arginine salt of (2s)-3-[4-[2-phenoxazin-10-yl)ethoxy] phenyl]2-ethoxypropanoic acid, processes for the preparation thereof and pharmaceutical compositions containing the same
AU3957900A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
AU3958100A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
IL145789A0 (en) 1999-04-20 2002-07-25 Novo Nordisk As Derivatives of propionic acid, their preparation and pharmaceutical compositions containing them
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
AU3957600A (en) 1999-04-26 2000-11-10 Boehringer Ingelheim International Gmbh Piperidyl-imidazole derivatives, their preparations and therapeutic uses
US6329336B1 (en) 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
CA2499211A1 (en) 1999-05-17 2000-11-23 Conjuchem Inc. Modified peptides yy and conjugates thereof
AU2001264791B2 (en) * 2000-06-16 2006-11-23 Eli Lilly And Company Glucagon-like peptide-1 analogs
PT1305301E (pt) 2000-07-20 2005-09-30 Hoffmann La Roche Benzeno-acetamidas alfa-acilo e alfa-heteroatomo-substituidas activadoras da glucocinase
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
IL161251A0 (en) 2001-10-10 2004-09-27 Neose Technologies Inc Remodeling and glycoconjugation of peptides
DE60315949T2 (de) 2002-01-16 2008-06-12 Biocompatibles Uk Ltd., Farnham Polymerkonjugate
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
MXPA05006994A (es) 2002-12-27 2005-10-18 Diobex Inc Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1503283A1 (en) 2003-08-01 2005-02-02 Hewlett-Packard Development Company, L.P. Data processing system and method
AU2004261353B2 (en) * 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
WO2005016974A1 (en) 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
CN101380476A (zh) 2003-09-19 2009-03-11 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
WO2005027978A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
BR122016022033B8 (pt) 2004-11-12 2021-05-25 Bayer Healthcare Llc conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica
CN101160326B (zh) 2005-02-23 2013-04-10 利普生技术有限公司 用于蛋白质衍生和缀合的活化的唾液酸衍生物
JP2008533104A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１受容体の二量体ペプチドアゴニスト
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP1871801A2 (en) 2005-04-01 2008-01-02 Novo Nordisk Health Care AG Blood coagulation fviii analogues
ES2385093T3 (es) 2005-06-13 2012-07-18 Imperial Innovations Limited Análogos de oxintomodulina y sus efectos sobre el comportamiento de la conducta alimentaria
WO2006134148A2 (en) 2005-06-15 2006-12-21 Novo Nordisk Health Care Ag Transglutaminase mediated conjugation of growth hormone
CN101222942A (zh) 2005-07-18 2008-07-16 诺沃-诺迪斯克有限公司 用于治疗肥胖的肽
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP1959986B1 (en) 2005-11-07 2014-07-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
EP1981977B1 (en) 2006-01-31 2015-12-23 National Research Council Of Canada Production of polysialic acid containing glyconjugates using a self-priming polysialyltransferase
EP1991574B1 (en) 2006-02-22 2016-10-12 Merck Sharp & Dohme Corp. Oxyntomodulin derivatives
CA2647314A1 (en) 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN103804489A (zh) 2006-12-15 2014-05-21 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
CN101578102B (zh) * 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
CN101790538B (zh) 2007-02-15 2014-07-30 印第安纳大学研究与科技公司 胰高血糖素/glp-1受体共激动剂
US20110177029A1 (en) 2007-06-04 2011-07-21 Novo Nordisk A/S O-linked glycosylation using n-acetylglucosaminyl transferases
JP5356373B2 (ja) 2007-06-15 2013-12-04 ナショナル リサーチ カウンシル オブ カナダ 酵素特性を向上させたポリシアリルトランスフェラーゼの操作されたバージョン
US7994122B2 (en) 2007-06-15 2011-08-09 Zealand Pharma A/S Glucagon analogues
CN101868476B (zh) 2007-09-05 2015-02-25 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
CN101842109B (zh) * 2007-09-05 2014-01-29 诺沃-诺迪斯克有限公司 用a-b-c-d-衍生的肽和它们的治疗用途
WO2009033769A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of cortistatin 14 and others as a therapeutic agent
US8173597B2 (en) 2007-11-09 2012-05-08 Baxter International Inc. Modified recombinant factor VIII and von Willebrand factor and methods of use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
EP2242505A4 (en) 2008-01-08 2012-03-07 Biogenerix Ag GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
JP5619630B2 (ja) 2008-02-27 2014-11-05 ノボ・ノルデイスク・エー／エス 結合型第ｖｉｉｉ因子分子
PA8830501A1 (es) * 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
SG192405A1 (en) 2008-06-17 2013-08-30 Univ Indiana Res & Tech Corp Gip-based mixed agonists for treatment of metabolic disorders and obesity
TWI541023B (zh) * 2008-06-17 2016-07-11 印第安納大學科技研究公司 在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
CN104829706A (zh) 2008-08-07 2015-08-12 益普生制药股份有限公司 糖依赖性胰岛素释放肽的类似物
US20100099616A1 (en) 2008-10-17 2010-04-22 Baxter International Inc. Modified blood factors comprising a low degree of water soluble polymer
JP5635532B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CA2747155A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
MA32970B1 (fr) * 2008-12-15 2012-01-02 Zealand Pharma As Analogues du glucagon
JP5635530B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CN102333788A (zh) 2009-02-19 2012-01-25 诺沃—诺迪斯克有限公司 因子viii的修饰
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
SG177609A1 (en) 2009-07-13 2012-02-28 Zealand Pharma As Acylated glucagon analogues
GB0917072D0 (en) * 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2552952A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
JP6026993B2 (ja) 2010-03-26 2016-11-16 ノヴォ ノルディスク アー／エス 新規のグルカゴンアナログ
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) * 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
MX2013007327A (es) 2010-12-22 2014-01-08 Marcadia Biotech Inc Metodos para tratar transtornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de gip y glp-1.
SG192038A1 (en) 2011-01-20 2013-08-30 Zealand Pharma As Combination of acylated glucagon analogues with insulin analogues
RU2013145013A (ru) * 2011-03-28 2015-05-10 Ново Нордиск А/С Новые аналоги глюкагона
EP2694095B1 (en) 2011-04-05 2018-03-07 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
KR102512178B1 (ko) 2011-05-18 2023-03-20 메더리스 다이어비티즈, 엘엘씨 개선된 펩티드 제약
KR102255479B1 (ko) 2011-05-18 2021-05-24 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
JP6014127B2 (ja) 2011-06-10 2016-10-25 ハンミ サイエンス カンパニー リミテッド 新規なオキシントモジュリン誘導体及びそれを含む肥満治療用組成物
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
ES2636445T3 (es) 2011-06-22 2017-10-05 Indiana University Research And Technology Corporation Coagonistas de receptores de glucagón/GLP-1
RU2610175C2 (ru) 2011-09-23 2017-02-08 Ново Нордиск А/С Новые аналоги глюкагона
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use

Also Published As

Publication number Publication date
CN104093735B (zh) 2018-07-06
WO2013041678A1 (en) 2013-03-28
RU2014114434A (ru) 2015-10-27
IL231199A0 (en) 2014-04-30
TW201329102A (zh) 2013-07-16
ZA201401603B (en) 2015-02-25
AU2012311484A1 (en) 2014-03-06
US9486505B2 (en) 2016-11-08
EP2758426B1 (en) 2019-08-07
US20160347812A1 (en) 2016-12-01
US8541368B2 (en) 2013-09-24
US20150182594A1 (en) 2015-07-02
JP6352806B2 (ja) 2018-07-04
EP2758426A1 (en) 2014-07-30
AR088161A1 (es) 2014-05-14
US20130288958A1 (en) 2013-10-31
US20130079278A1 (en) 2013-03-28
CA2849673A1 (en) 2013-03-28
BR112014006684A2 (pt) 2017-03-28
KR20140070612A (ko) 2014-06-10
MY167234A (en) 2018-08-14
JP2014527975A (ja) 2014-10-23
MX2014003312A (es) 2014-04-25
US9486506B2 (en) 2016-11-08
JP2018021081A (ja) 2018-02-08
RU2610175C2 (ru) 2017-02-08
TWI596110B (zh) 2017-08-21
CN104093735A (zh) 2014-10-08
AU2012311484B2 (en) 2017-04-13
RU2017101333A (ru) 2018-12-19
MX354705B (es) 2018-03-16

Similar Documents

Publication Publication Date Title
IN2014CN02448A (bg)
MX2013011175A (es) Analogos de glucagon novedosos.
MX336412B (es) Nuevos analogos de glucagon.
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX2014015423A (es) Analogos de peptido de exedina-4.
MX2015008114A (es) Derivados de exendina-4.
IL239488B (en) A gpc3-targeted medicinal agent administered to a patient who responds to treatment with a gpc3-targeted medicinal agent
PH12014502058A1 (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
ZA201505849B (en) Composition of novel carbohydrate drug for treatment of human diseases
EA201201657A1 (ru) Лечение диабета
NZ719520A (en) Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
HK1208830A1 (en) Drug delivery device for the treatment of patients with respiratory diseases
PH12019501363A1 (en) Insulin containing pharmaceutical compositions
IN2014KN02335A (bg)
AU2013298343A8 (en) Targeted oesophageal administration of Zn-alpha2-glycoproteins (ZAG), methods and formulations thereof
PL2852400T3 (pl) Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym, zastosowanie analogu insuliny, sposób dawkowania oraz sposób leczenia cukrzycy
GB201304462D0 (en) Therapeutic vaccine for treatment of type 2 diabetes and impaired glucose tolerance
UA53217U (en) Mask for therapy and general health improvement
UA53455U (ru) Способ лечения некоторых дерматозов
UA78287U (ru) Способ медицинской реабилитации больных ишемической болезнью сердца на фоне метаболического синдрома